Patent intelligence · US
US 11191758
Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors
Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors
Patent details — US 11191758
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 7, 2021
- Expiration
- Dec 2, 2041
- Claims
- 6
- CPC classes
- A61K, A61K31/135, A61K31/428, A61K31/435
Quick answer
US 11191758 (Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors) is held by Uniwersytet Jagiellonski Collegium Medicum. Status: granted. Granted Dec 7, 2021. Expires Dec 2, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K31/135, A61K31/428, A61K31/435, A61K31/4418, A61K31/4433
More from Uniwersytet Jagiellonski Collegium Medicum
Related pharmaceutical patents in our USPTO index.
-
US 10668060
Tamper-resistant pharmaceutical compositions of opioids and other drugs
granted -
US 10646485
Process of making stable abuse-deterrent oral formulations
granted -
US 10525052
Abuse-deterrent drug formulations
granted -
US 10525053
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
granted -
US 10188644
Process of making stable abuse-deterrent oral formulations
granted -
US 10004729
Tamper-resistant pharmaceutical compositions of opioids and other drugs
granted -
US 9968598
Process of making stable abuse-deterrent oral formulations
granted
Frequently asked questions
What is US patent 11191758?
US 11191758 (Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors) is held by Uniwersytet Jagiellonski Collegium Medicum. Status: granted. Granted Dec 7, 2021. Expires Dec 2, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11191758?
Uniwersytet Jagiellonski Collegium Medicum is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 28 pharmaceutical patents for this assignee.
When does US 11191758 expire?
Our index shows an expiration date of Dec 2, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.